Despite many electrophysiologists' enthusiasm for less-invasive cardiac rhythm management devices, insurers are frequently denying coverage of Boston Scientific's Emblem subcutaneous implantable cardioverter defibrillator (S-ICD) for patients, citing what they argue is a lack of adequate clinical data that shows them to be better than "experimental." Boston Scientific recently sponsored a virtual roundtable of physicians to discuss how new professional society guidelines are influencing prescribing and reimbursement of these devices.
Boston Scientific's Emblem S-ICD in an anatomical illustration. • Source: Boston Scientific
Boston Scientific Corp.'s Emblem subcutaneous implantable cardioverter defibrillator (S-ICD) earned FDA approval in 2013. In 2017 professional society guidelines were issued on the management of ventricular arrhythmias and the prevention of sudden cardiac death that recommend S-ICDs for some patients. However, many payers still consider it an "experimental" therapy for the purposes of coverage.
Boston Scientific added the S-ICD technology to its portfolio when it acquired Cameron Health in 2012. (Also see "Exec...
Keep up with the top medtech business and regulatory news.
Medtech Insight brings you interviews and analysis, on the go.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
